BOSTON--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, reported today on Bendavia study findings presented during the annual American Society of Nephrology (ASN) meeting. Bendavia™ is a novel compound that targets the mitochondrion to treat mitochondrial dysfunction including ischemia reperfusion and microvascular injuries. ASN is a U.S. nonprofit organization that leads the fight against kidney disease by educating healthcare professionals and advancing basic and clinical research. ASN’s “Kidney Week 2011” meeting was held November 8th through November 13th in Philadelphia, where over 13,000 nephrology professionals gathered to exchange knowledge and learn the latest on scientific and medical advances.
